Lars Fruergaard Jørgensen is the CEO of Novo Nordisk. He and the other management have had to lower expectations for the year's sales growth due to tough competition in the weight loss market in the USA. (Archive photo). Photo: Tom Little/Reuters
Novo lowers expectations amid US market pressure
Novo Nordisk has lowered its financial expectations for 2025 due to competition from companies legally producing copies of its weight loss drug, Wegovy. Initially, the company expected a sales growth of 16 to 24 percent, but now anticipates growth of only 13 to 21 percent due to a...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?